SELLAS Life Sciences Group, Inc.
SLSDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
SLS Earnings Report
FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How SLS's past catalysts played out
Galinpepimut-S
Acute Myeloid Leukemia
Decitabine
Acute Myeloid Leukemia
pembrolizumab
Acute Myelogenous Leukemia
Galinpepimut-S + Montanide + GM-CSF
Malignant Pleural Mesothelioma
lenalidomide
Multiple Myeloma
SLS009
Hematologic Malignancies
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Galinpepimut-S | Phase 3 | Acute Myeloid Leukemia | - | - |
Decitabine | Phase 3 | Acute Myeloid Leukemia | - | - |
pembrolizumab | Phase 2 | Acute Myelogenous Leukemia | - | - |
Galinpepimut-S + Montanide + GM-CSF | Phase 2 | Malignant Pleural Mesothelioma | - | - |
lenalidomide | Phase 2 | Multiple Myeloma | - | - |
SLS009 | Phase 2 | Hematologic Malignancies | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SELLAS Life Sciences Group, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in SELLAS Life Sciences Group, Inc.'s (SLS) pipeline across Phase 3, Phase 2. Its lead program is Galinpepimut-S (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SELLAS Life Sciences Group, Inc.'s next FDA catalyst?→
SELLAS Life Sciences Group, Inc.'s (SLS) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SLS biotech catalysts?→
Add SLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SELLAS Life Sciences Group, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.